Actos pioglitazone: Phase III started
Takeda and Zinfandel Pharmaceuticals Inc. (Durham, N.C.) began the double-blind, international Phase III TOMMORROW trial of oral AD-4833 once daily for up to 5 years and the biomarker risk assignment algorithm in about 5,800 cognitively normal subjects ages 65-83. Subjects who are assessed as low risk by the biomarker risk assignment algorithm will receive placebo while those assessed as high risk will receive AD-4833 or placebo. AD-4833 is marketed as Actos pioglitazone for Type II diabetes. The genetic-based biomarker risk assignment algorithm is based on apolipoprotein E (APOE) and translocase of outer mitochondrial membrane 40 homolog ( TOMM40; TOM40) genotypes and age, and is being evaluated in the trial to determine the risk of individuals developing MCI due to AD within 5 years. ...